Vascular Disease in Scleroderma

Although scleroderma is generally considered a fibrosing disease of the tissues, it is now recognized that the underlying vascular disease is playing a fundamental role in its pathogenesis and associated tissue injury. The exact mechanism for the widespread scleroderma vascular disease is still unknown, but endothelial cell injury induced by infection, immune-mediated cytotoxicity, antiendothelial antibodies, and/or ischemia-reperfusion have all been implicated. The downstream effects of blood vessel perturbation produce “biomarkers” of vascular damage that reflect disease and may predict clinical outcomes. A complex interaction between endothelial cells, smooth muscle cells, extracellular matrix, and intravascular circulating factors is now recognized to contribute to the vascular reactivity, remodeling, and occlusive disease of scleroderma. Understanding the mechanisms underlying these processes provides rationale of novel therapeutic strategies and specific targeted therapy. This review will outline some of the evidence for the causes and consequences of scleroderma vascular disease.

[1]  S. Kumar,et al.  The TGF beta receptor endoglin in systemic sclerosis. , 2001, Asian Pacific journal of allergy and immunology.

[2]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[3]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[4]  E. Colantuoni,et al.  Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. , 2009, Arthritis and rheumatism.

[5]  B. Kahaleh Vascular disease in scleroderma: mechanisms of vascular injury. , 2008, Rheumatic diseases clinics of North America.

[6]  Y. Shoenfeld,et al.  Heat‐Shock Protein 65 Autoantibodies Are Differently Associated with Early Atherosclerosis in Rheumatoid Arthritis and in Healthy Subjects , 2007, Annals of the New York Academy of Sciences.

[7]  G. Mancia,et al.  Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis , 2007 .

[8]  S. Migliaresi,et al.  Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. , 1995, Autoimmunity.

[9]  V. Gurevich Influenza, autoimmunity and atherogenesis. , 2005, Autoimmunity reviews.

[10]  R Fleischmajer,et al.  Capillary alterations in scleroderma. , 1980, Journal of the American Academy of Dermatology.

[11]  M. Cutolo,et al.  Nailfold video-capillaroscopy in systemic sclerosis , 2004, Zeitschrift für Rheumatologie.

[12]  Oliver Distler,et al.  Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. , 2008, Arthritis and rheumatism.

[13]  Michael Simons,et al.  Antiangiogenic plasma activity in patients with systemic sclerosis. , 2007, Arthritis and rheumatism.

[14]  C. Wiener,et al.  Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. , 2000, Arthritis and rheumatism.

[15]  T. Medsger,et al.  Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. , 1989, The Journal of rheumatology.

[16]  S. Flavahan,et al.  Silent α2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries , 2000 .

[17]  C. Penning,et al.  Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. , 1984, Clinical and experimental immunology.

[18]  Oliver Distler,et al.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.

[19]  V. Welch,et al.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. , 2001, Arthritis and rheumatism.

[20]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.

[21]  S. Marshall,et al.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. , 2001, Rheumatology.

[22]  P. Woo,et al.  Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. , 1988, Clinical and experimental immunology.

[23]  T. Sycha,et al.  Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study , 2004, European journal of clinical investigation.

[24]  P. Cannon,et al.  THE RELATIONSHIP OF HYPERTENSION AND RENAL FAILURE IN SCLERODERMA (PROGRESSIVE SYSTEMIC SCLEROSIS) TO STRUCTURAL AND FUNCTIONAL ABNORMALITIES OF THE RENAL CORTICAL CIRCULATION , 1974, Medicine.

[25]  R. Macko,et al.  Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.

[26]  B. Bottasso,et al.  Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. , 1992, International journal of microcirculation, clinical and experimental.

[27]  G. Burnstock,et al.  Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. , 2004, Clinical and experimental rheumatology.

[28]  R. De Angelis,et al.  Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. , 2001, Scandinavian journal of rheumatology.

[29]  S. Basili,et al.  Autonomic dysfunction and microvascular damage in systemic sclerosis , 2007, Clinical Rheumatology.

[30]  J. Morrow,et al.  Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. , 1996, Arthritis and rheumatism.

[31]  G. Hutchins,et al.  Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. , 1978, American heart journal.

[32]  G. Rodnan,et al.  Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. , 1980, Medicine.

[33]  D. Collier,et al.  Anticardiolipin antibodies in scleroderma. , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[34]  S. Goland,et al.  Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. , 2007, The American journal of cardiology.

[35]  J. Fries,et al.  Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.

[36]  D. Borderie,et al.  Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. , 2008, Rheumatology.

[37]  Leroy Ec,et al.  Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc) , 1999 .

[38]  M. Fujimoto,et al.  A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the Disease , 2006, Dermatology.

[39]  J. Piette,et al.  The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. , 1998, The Journal of clinical investigation.

[40]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[41]  A. Merla,et al.  Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. , 2007, The Journal of rheumatology.

[42]  K. Takehara,et al.  Elevated plasma endothelin levels in systemic sclerosis , 2004, Archives of Dermatological Research.

[43]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[44]  M. Cutolo,et al.  Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients , 2007, Annals of the rheumatic diseases.

[45]  D. Borderie,et al.  Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis , 2004, Arthritis research & therapy.

[46]  L. Hummers Biomarkers of vascular disease in scleroderma. , 2008, Rheumatology.

[47]  A. Zalewska,et al.  Correlation of Endostatin and Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Serum Levels With Cardiovascular Involvement in Systemic Sclerosis Patients , 2005, Mediators of inflammation.

[48]  G. Wick,et al.  Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). , 2000, Journal of autoimmunity.

[49]  J. Lekakis,et al.  Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. , 1998, The American journal of cardiology.

[50]  Maricq Hr,et al.  Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. , 1982 .

[51]  R. Abbate,et al.  Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. , 2007, Rheumatology.

[52]  J. Pearson,et al.  Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. , 1998, QJM : monthly journal of the Association of Physicians.

[53]  B. Kahaleh The microvascular endothelium in scleroderma. , 2008, Rheumatology.

[54]  D. Abraham,et al.  Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. , 2001, The Journal of clinical investigation.

[55]  R. Barst PDGF signaling in pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[56]  A. Kuryliszyn-Moskal,et al.  A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis , 2006, Clinical Rheumatology.

[57]  E. Hurd,et al.  Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. , 1983, Arthritis and rheumatism.

[58]  D. Ribatti,et al.  Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane , 2005, Clinical Rheumatology.

[59]  A. Freemont,et al.  Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. , 1994, Annals of the rheumatic diseases.

[60]  R. D. du Bois,et al.  Exhaled nitric oxide is increased in active fibrosing alveolitis. , 1999, Chest.

[61]  R. Fine Cytotoxicity of sera from patients with scleroderma--effects on human endothelial cells and fibroblasts in culture. , 1984, International journal of dermatology.

[62]  R. Koppensteiner,et al.  Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. , 2006, Clinical rheumatology.

[63]  N. Sepp,et al.  Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. , 2000, Arthritis and rheumatism.

[64]  M. Fujimoto,et al.  Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. , 1997, British journal of rheumatology.

[65]  Leroy Ec,et al.  Endothelial injury in scleroderma. A protease mechanism. , 1983 .

[66]  M. Matucci-Cerinic,et al.  Estrogens and neuropeptides in Raynaud's phenomenon. , 2005, Rheumatic diseases clinics of North America.

[67]  C. Black,et al.  Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. , 2006, Rheumatology.

[68]  A. Rosen,et al.  Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis , 1997, The Journal of experimental medicine.

[69]  C. Denton,et al.  Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. , 1999, Rheumatology.

[70]  R. Koppensteiner,et al.  Predictive value of naitfold capillaroscopy in patients with Raynaud’s phenomenon , 2006, Clinical Rheumatology.

[71]  H. Maricq,et al.  Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population. , 2006, Journal of vascular surgery.

[72]  J. Murabito,et al.  The incidence and natural history of Raynaud's phenomenon in the community. , 2005, Arthritis and rheumatism.

[73]  M. Kahaleh,et al.  Endothelial injury in scleroderma , 1979, The Journal of experimental medicine.

[74]  M. Matucci-Cerinic,et al.  Digital ulcers and outcomes assessment in scleroderma. , 2008, Rheumatology.

[75]  E. Hachulla,et al.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. , 2007, The Journal of rheumatology.

[76]  A. Freemont,et al.  The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. , 2006, Human pathology.

[77]  H. Krasa,et al.  Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study , 2004 .

[78]  C. Pearson,et al.  Rheumatic disease sera reactive with capillaries in the mouse kidney. , 1972, Arthritis and rheumatism.

[79]  B. Weill,et al.  Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. , 2005, Clinical and experimental rheumatology.

[80]  M. Fujimoto,et al.  Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. , 1998, British journal of rheumatology.

[81]  M. Greaves,et al.  Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. , 1989, Clinical and experimental immunology.

[82]  S. Jimenez,et al.  Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[83]  R. Barst,et al.  Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[84]  A. Herrick,et al.  The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. , 2001, Clinical and experimental rheumatology.

[85]  L. Andrade,et al.  Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. , 2007, Rheumatology.

[86]  V. Fonollosa-Plá,et al.  Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis , 2008, Annals of the rheumatic diseases.

[87]  K. Welsh,et al.  Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. , 1996, The Journal of rheumatology.

[88]  D. Abraham,et al.  How does endothelial cell injury start? The role of endothelin in systemic sclerosis , 2007, Arthritis research & therapy.

[89]  R. L. Linscheid,et al.  Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5‐hydroxytryptamine , 1976, The British journal of dermatology.

[90]  Francesco Boin,et al.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.

[91]  T. King,et al.  Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. , 2002, Rheumatology.

[92]  D. Veale,et al.  Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. , 1998, British journal of rheumatology.

[93]  C. Savage,et al.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. , 1996, The Journal of clinical investigation.

[94]  P. Bruneval,et al.  Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS) , 2004, Archives of Dermatological Research.

[95]  T. Medsger,et al.  Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. , 1988, Arthritis and rheumatism.

[96]  A. Blann,et al.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. , 1999, Arthritis and rheumatism.

[97]  M. Cerinic,et al.  Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. , 2007, Arthritis and rheumatism.

[98]  M. Cerinic,et al.  Raynaud's phenomenon and vascular disease in systemic sclerosis. , 1999, Advances in experimental medicine and biology.

[99]  A. Gabrielli,et al.  Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. , 2001, The Journal of rheumatology.

[100]  M. Jayson,et al.  Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy , 1992, The British journal of dermatology.

[101]  J. Cooke,et al.  Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma , 2000, Vascular medicine.

[102]  S. Yamazaki,et al.  Cutaneous localization of endothelin‐1 in patients with systemic sclerosis: immunoelectron microscopic study , 1997, International journal of dermatology.

[103]  H. Maricq,et al.  Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud's syndrome. , 1976, Blood vessels.

[104]  R. Mason Effects of calcium channel blockers on cellular apoptosis , 1999, Cancer.

[105]  C. Denton,et al.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. , 1995, British journal of rheumatology.

[106]  M. Jayson,et al.  Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin , 1999, The Journal of pathology.

[107]  F. V. D. van den Hoogen,et al.  Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[108]  S. Flavahan,et al.  Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. , 2005, American journal of physiology. Heart and circulatory physiology.

[109]  K. Nishioka,et al.  Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. , 1998, The Journal of rheumatology.

[110]  J. Varga,et al.  Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers , 2006, Expert opinion on pharmacotherapy.

[111]  J. Weiss,et al.  Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. , 1986, Annals of internal medicine.

[112]  K. Nishioka,et al.  Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. , 1990, Journal of the American Academy of Dermatology.

[113]  Tonia Moore,et al.  Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. , 2005, The Journal of rheumatology.

[114]  P. Sfikakis,et al.  Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. , 1993, Clinical immunology and immunopathology.

[115]  J. Seibold,et al.  Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. , 1984, Arthritis and rheumatism.

[116]  R. Sjogren,et al.  Gastrointestinal motility disorders in scleroderma. , 1994, Arthritis and rheumatism.

[117]  C. Bunker,et al.  Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon , 1993, The Lancet.

[118]  M. Kahaleh,et al.  Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. , 1997, Clinical immunology and immunopathology.

[119]  J. Piette,et al.  Antiendothelial cell antibodies: useful markers of systemic sclerosis. , 1997, The American journal of medicine.

[120]  J. Egido,et al.  Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.

[121]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[122]  N. Flavahan Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. , 2008, Rheumatic diseases clinics of North America.

[123]  Walter Grassi,et al.  Capillaroscopy: questions and answers , 2007, Clinical Rheumatology.

[124]  X. Zheng,et al.  Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of scleroderma , 1998 .

[125]  S. Barnum,et al.  Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). , 2000, The Journal of rheumatology.

[126]  R. Scorza,et al.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. , 2001, Clinical and experimental rheumatology.

[127]  C. Black,et al.  Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. , 1995, Arthritis and rheumatism.

[128]  A. Koch,et al.  Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis , 2007, Arthritis research & therapy.

[129]  M. Vilardell,et al.  Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. , 1991, The Journal of rheumatology.

[130]  T. Williams,et al.  Cutaneous blood flow responses in the forearms of Raynaud's patients induced by local cooling and intradermal injections of CGRP and histamine. , 1990, British journal of clinical pharmacology.

[131]  G. Hutchins,et al.  A case–control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma) , 2006, Gut.

[132]  Orris,et al.  INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .

[133]  C. Denton,et al.  Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis , 2007, Annals of the rheumatic diseases.

[134]  A. Abidia Endothelial Cell Responses To Hypoxic Stress , 2000, Clinical and experimental pharmacology & physiology.

[135]  O. Kowal‐Bielecka,et al.  The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis--preliminary report. , 2005, Roczniki Akademii Medycznej w Bialymstoku.

[136]  M. Cerinic,et al.  Reduced circulating levels of angiotensin-(1–7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control , 2007, Annals of the rheumatic diseases.

[137]  B. Roussel,et al.  Anti-beta 2-glycoprotein I antibodies. , 1995, Clinical reviews in allergy & immunology.

[138]  M. Simons,et al.  Current concepts in normal and defective angiogenesis: Implications for systemic sclerosis , 2007, Current rheumatology reports.

[139]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[140]  J. F. Wolfe,et al.  Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. , 1980, Arthritis and rheumatism.

[141]  T. Koike,et al.  Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study , 2006, Annals of the rheumatic diseases.

[142]  I. Goldstein,et al.  Systemic sclerosis and impotence: a clinicopathological correlation. , 1995, The Journal of urology.

[143]  B. Giusti,et al.  A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients , 2006, Arthritis research & therapy.

[144]  M. Kahaleh,et al.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. , 1981, Annals of internal medicine.

[145]  M. Gruschwitz,et al.  Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.

[146]  C. Junien,et al.  Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. , 2006, Rheumatology.

[147]  M. Mayes,et al.  Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. , 1999, The Journal of rheumatology.

[148]  L. Rudnicka,et al.  Cytotoxic effects of sera from patients with systemic scleroderma: Comparison of three different in vitro methods , 2005, Rheumatology International.

[149]  P. Helmbold,et al.  Hyperplasia of dermal microvascular pericytes in scleroderma * , 2004, Journal of cutaneous pathology.

[150]  W. Roberts,et al.  Atherosclerotic Narrowing of the Left Main Coronary Artery: A Necropsy Analysis of 152 Patients with Fatal Coronary Heart Disease and Varying Degrees of Left Main Narrowing , 1976, Circulation.

[151]  M. Harigai,et al.  Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. , 1999, The Journal of rheumatology.

[152]  R. Gomer Circulating progenitor cells and scleroderma , 2008, Current rheumatology reports.

[153]  R. Fleischmajer,et al.  [3H]Thymidine labeling of dermal endothelial cells in scleroderma. , 1977, The Journal of investigative dermatology.

[154]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[155]  M. Mayes,et al.  Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma , 1999, The Lancet.

[156]  N. Suzuki,et al.  Significance of plasma endothelin-1 levels in patients with systemic sclerosis. , 1992, The Journal of rheumatology.

[157]  C. Stefanadis,et al.  Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. , 2007, Arthritis and rheumatism.

[158]  A. Postlethwaite,et al.  Platelet contributions to the pathogenesis of systemic sclerosis , 2007, Current opinion in rheumatology.

[159]  C. Bunker,et al.  Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon , 1990, The Lancet.

[160]  A. Gabrielli,et al.  Bone marrow endothelial progenitors are defective in systemic sclerosis. , 2006, Arthritis and rheumatism.

[161]  A. Herrick,et al.  Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. , 1994, The Journal of rheumatology.

[162]  B. Satiani,et al.  Three cases of digital ischemia successfully treated with cilostazol , 2001, Vascular medicine.

[163]  G. Damonte,et al.  Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells , 2000, Nature Medicine.

[164]  J. Pope,et al.  The frequency and significance of anticardiolipin antibodies in scleroderma. , 2000, The Journal of rheumatology.

[165]  G. Hughes,et al.  The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. , 1997, British journal of rheumatology.

[166]  H. Tse,et al.  Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis , 2008, Clinical Rheumatology.

[167]  J. Jespersen,et al.  Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. , 1989, Scandinavian journal of rheumatology.

[168]  H. Krasa,et al.  Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. , 2004, Arthritis & Rheumatism.

[169]  M. Greaves,et al.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.

[170]  Judy W. M. Cheng Ambrisentan for the management of pulmonary arterial hypertension. , 2008, Clinical therapeutics.

[171]  L. Klareskog,et al.  Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. , 1990, Arthritis and rheumatism.

[172]  G. Pamuk,et al.  Increased circulating platelet–leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[173]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[174]  M. Cerinic,et al.  Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. , 2003, Seminars in arthritis and rheumatism.

[175]  M. Pastor,et al.  Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia. , 2003, Rheumatology.

[176]  J. Egido,et al.  Molecular mechanisms of angiotensin II-induced vascular injury , 2003, Current hypertension reports.

[177]  Soo-Kon Lee,et al.  Antiphospholipid Syndrome Associated with Progressive Systemic Sclerosis , 1996, The Journal of dermatology.

[178]  H. Maricq,et al.  Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. , 1973, Arthritis and rheumatism.

[179]  James Allen,et al.  The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. , 2007, American journal of clinical pathology.

[180]  P. Altmeyer,et al.  Macroangiopathy of the upper extremities in progressive systemic sclerosis. , 2000, European journal of medical research.

[181]  S. Svegliati,et al.  Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited , 2008, Seminars in Immunopathology.

[182]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[183]  M. Petri,et al.  Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[184]  L. Rudnicka,et al.  Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). , 1992, Arthritis & Rheumatism.

[185]  C. Denton,et al.  Angiographically proven coronary artery disease in scleroderma. , 2006, Rheumatology.

[186]  T. Medsger,et al.  Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. , 1984, The New England journal of medicine.

[187]  H. Maricq,et al.  Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. , 1982, The Journal of rheumatology.

[188]  Y. Ikeda,et al.  Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. , 2006, Arthritis and rheumatism.

[189]  T. King,et al.  Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. , 2006, Arthritis and rheumatism.

[190]  M. Mayes,et al.  Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. , 2001, The Journal of rheumatology.

[191]  S. Rantapää-Dahlqvist,et al.  Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. , 2000, Arthritis and rheumatism.

[192]  F. Ingegnoli,et al.  Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. , 2004, Arthritis and rheumatism.

[193]  M. Greaves,et al.  Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. , 1988, Clinical and experimental immunology.

[194]  R. Barst,et al.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[195]  Y. Konttinen,et al.  Vascular damage and lack of angiogenesis in systemic sclerosis skin , 2003, Clinical Rheumatology.

[196]  A. Kahan,et al.  Increased nitric oxide in exhaled air in patients with systemic sclerosis. , 1998, Clinical and experimental rheumatology.

[197]  B. Giusti,et al.  The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. , 2005, Arthritis and rheumatism.

[198]  O. Hornstein,et al.  Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. , 1995, Arthritis and rheumatism.

[199]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[200]  C. Denton,et al.  Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.

[201]  D. Nowak,et al.  Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis--association with pulmonary involvement. , 2006, Clinical and experimental rheumatology.

[202]  H. Mizutani,et al.  Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. , 1996, Acta medica Okayama.

[203]  S. Flavahan,et al.  Rho Kinase Mediates Cold-Induced Constriction of Cutaneous Arteries: Role of &agr;2C-Adrenoceptor Translocation , 2004, Circulation research.

[204]  Stephen M. Schwartz,et al.  Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? , 2008, PloS one.

[205]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[206]  H. Sallam,et al.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma) , 2006, Alimentary pharmacology & therapeutics.

[207]  A. Silman,et al.  Factor VIII related antigen in connective tissue disease patients and relatives. , 1990, British journal of rheumatology.

[208]  D. Veale,et al.  Macrovascular disease and systemic sclerosis , 2000, Annals of the rheumatic diseases.

[209]  H. Herzog,et al.  Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. , 1995, Canadian journal of physiology and pharmacology.

[210]  L. Chung,et al.  A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. , 2006, Journal of the American Academy of Dermatology.

[211]  J. Stockman,et al.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .

[212]  A. Silman,et al.  Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.

[213]  M. Nishimura,et al.  Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[214]  R. Hesselstrand,et al.  Simple counting of nailfold capillary density in suspected systemic sclerosis – 9 years' experience , 2007, Scandinavian journal of rheumatology.

[215]  R. Benza,et al.  Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[216]  J. Korn,et al.  Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. , 1982, Arthritis and rheumatism.

[217]  S. Jimenez,et al.  Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? , 2006, Autoimmunity reviews.

[218]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[219]  T Moore,et al.  Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. , 1995, British journal of rheumatology.

[220]  S. Yousem The pulmonary pathologic manifestations of the CREST syndrome. , 1990, Human pathology.

[221]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[222]  L. Mouthon,et al.  Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). , 2006, Clinical immunology.

[223]  M. Simons,et al.  Vascular disease in scleroderma: angiogenesis and vascular repair. , 2008, Rheumatic diseases clinics of North America.

[224]  V. Rajkumar,et al.  Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. , 1999, Arthritis and rheumatism.

[225]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[226]  M. Roustit,et al.  Abnormal digital neurovascular response to local heating in systemic sclerosis. , 2008, Rheumatology.

[227]  M. Cerinic,et al.  Vascular complications of scleroderma. , 2007, Autoimmunity reviews.

[228]  L. Stafford,et al.  Distribution of macrovascular disease in scleroderma , 1998, Annals of the rheumatic diseases.

[229]  M. Kahaleh,et al.  Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. , 1986, Clinical immunology and immunopathology.

[230]  M. Fujimoto,et al.  Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis , 2000, Clinical and experimental immunology.

[231]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[232]  C. Cho,et al.  Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts , 2006, Clinical and experimental immunology.

[233]  D. Knight,et al.  The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. , 2003, American journal of clinical pathology.

[234]  J. Shaver,et al.  Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). , 1977, Annals of internal medicine.

[235]  Malcolm D. Smith,et al.  Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis , 2005, Pathology.

[236]  E. Leroy SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[237]  K. Stengaard-Pedersen,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. , 1998, British journal of rheumatology.

[238]  K. Shaw,et al.  Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidine. , 1976, Archives of dermatology.

[239]  C. Denton,et al.  Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. , 2000, Clinical and experimental rheumatology.

[240]  A. Silman,et al.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.

[241]  B. Weill,et al.  Levels of circulating endothelial progenitor cells in systemic sclerosis. , 2007, Clinical and experimental rheumatology.

[242]  A. Guttmacher,et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.

[243]  H. Shigemitsu,et al.  Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis , 2004, Current opinion in rheumatology.

[244]  J. Catravas,et al.  Pulmonary capillary endothelial dysfunction in early systemic sclerosis. , 2001, Arthritis and rheumatism.

[245]  P. Merkel,et al.  The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. , 1996, The American journal of medicine.

[246]  C. Kallenberg,et al.  Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease. , 1986, The Journal of rheumatology.

[247]  Hiroshi Watanabe,et al.  Sildenafil for primary and secondary pulmonary hypertension , 2002, Clinical pharmacology and therapeutics.

[248]  S. Gay,et al.  Angiogenesis and vasculogenesis in systemic sclerosis. , 2006, Rheumatology.

[249]  A. Brucato,et al.  Anti-cardiolipin antibodies in progressive systemic sclerosis (PSS) , 1987, Clinical and experimental rheumatology.

[250]  M. Cinelli,et al.  Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.

[251]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[252]  M. Kahaleh,et al.  Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. , 1982, Annals of internal medicine.

[253]  M. Fujimoto,et al.  Elevated circulating CD40L concentrations in patients with systemic sclerosis. , 2004, The Journal of rheumatology.

[254]  A. Smit,et al.  Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. , 1994, Seminars in arthritis and rheumatism.

[255]  L. Fraenkel,et al.  The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women , 1998, Annals of Internal Medicine.

[256]  R. Silver Endothelin and scleroderma lung disease. , 2008, Rheumatology.

[257]  G. Faccani,et al.  Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. , 1984, Clinical and experimental rheumatology.

[258]  H. Deicher,et al.  Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus , 2004, Rheumatology International.

[259]  G. Mancia,et al.  Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. , 2007, Journal of hypertension.

[260]  R. Wise,et al.  Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. , 1992, Arthritis and rheumatism.

[261]  P. Furspan,et al.  Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. , 2004, Arthritis and rheumatism.

[262]  Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. , 2008, Rheumatology.

[263]  K. Yamane Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. , 1994, Internal medicine.

[264]  M. Aringer,et al.  Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. , 1994, Clinical and experimental rheumatology.

[265]  M. Rizzo,et al.  [Digital ulcers in a cohort of 333 scleroderma patients]. , 2011, Reumatismo.

[266]  G. Mark,et al.  Pulmonary vascular changes in scleroderma. , 1978, The American journal of medicine.

[267]  M. Baron,et al.  Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. , 2008, Arthritis and rheumatism.

[268]  G. FitzGerald,et al.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. , 1986, British medical journal.

[269]  A. Hasegawa,et al.  Autopsy case of systemic sclerosis with severe pulmonary hypertension , 2007, Journal of dermatology (Print).

[270]  P. Ryan,et al.  Antiphospholipid syndrome in scleroderma. , 1993, Journal of Rheumatology.

[271]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[272]  R. Silver,et al.  Ulnar artery involvement in systemic sclerosis (scleroderma). , 2002, The Journal of rheumatology.

[273]  J D Coffman,et al.  Total and capillary fingertip blood flow in Raynaud's phenomenon. , 1971, The New England journal of medicine.

[274]  J. van der Meer,et al.  A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. , 1987, VASA. Supplementum.

[275]  M. Kahaleh,et al.  Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. , 1991, Arthritis and rheumatism.

[276]  S. Flavahan,et al.  Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. , 2000, American journal of physiology. Heart and circulatory physiology.

[277]  M. Cerinic,et al.  Flow‐Mediated Vasodilation and Carotid Intima‐Media Thickness in Systemic Sclerosis , 2007, Annals of the New York Academy of Sciences.

[278]  V. Fuster,et al.  Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. , 1984, Arthritis and rheumatism.

[279]  I. Marie,et al.  Anticardiolipin and anti‐β2 glycoprotein I antibodies and lupus‐like anticoagulant: prevalence and significance in systemic sclerosis , 2007, The British journal of dermatology.

[280]  A. Blann,et al.  A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. , 2000, Clinical and experimental rheumatology.

[281]  M. Jayson,et al.  Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. , 1993, The Journal of rheumatology.

[282]  M. Ehrenfeld,et al.  A Novel Overlap Syndrome , 2007, Annals of the New York Academy of Sciences.

[283]  R. Moots,et al.  Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. , 2007, Arthritis and rheumatism.

[284]  I M Braverman,et al.  Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. , 1983, The Journal of investigative dermatology.

[285]  O. Hornstein,et al.  Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. , 1992, Journal of the American Academy of Dermatology.

[286]  W. L. Norton,et al.  Vascular disease in progressive systemic sclerosis (scleroderma). , 1970, Annals of internal medicine.

[287]  Y. Shoenfeld,et al.  Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. , 2003, Human Antibodies.

[288]  S. Abou-Raya,et al.  Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. , 2008, The Journal of rheumatology.

[289]  J. Johnson,et al.  Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. , 1991, The Journal of investigative dermatology.

[290]  L. Hornez,et al.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[291]  M. Creager,et al.  International study of ketanserin in Raynaud's phenomenon. , 1989, The American journal of medicine.

[292]  V. Negi,et al.  Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. , 1998, The Journal of rheumatology.

[293]  S. Bombardieri,et al.  Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. , 2008, Rheumatology.

[294]  S. Schwartz,et al.  The pathology of scleroderma vascular disease. , 2008, Rheumatic diseases clinics of North America.

[295]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[296]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[297]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[298]  A. Hobson,et al.  Investigation of anal function in patients with systemic sclerosis. , 1996, Annals of the rheumatic diseases.

[299]  G. Hunder,et al.  Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[300]  M. Gershwin,et al.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. , 1996, The Journal of clinical investigation.

[301]  M. Morfini,et al.  Cutaneous and Plasma Fibrinolytic Activity in Systemic Sclerosis , 1990, International journal of dermatology.

[302]  M. Matucci-Cerinic,et al.  Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. , 1998, Clinical and experimental rheumatology.

[303]  P. Youssef,et al.  Large vessel occlusive disease associated with CREST syndrome and scleroderma. , 1993, Annals of the rheumatic diseases.

[304]  R. D. du Bois,et al.  Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. , 1997, Thorax.

[305]  K. Csiszȧr,et al.  Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis , 2005, Arthritis research & therapy.

[306]  N. Harris,et al.  Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. , 2007, Rheumatology.

[307]  S. Sato,et al.  Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. , 2007, Clinical and experimental rheumatology.

[308]  M. Kahaleh,et al.  Endothelial injury in scleroderma. A protease mechanism. , 1983, The Journal of laboratory and clinical medicine.

[309]  A. Sasseville,et al.  Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1 , 2005, The Journal of Immunology.

[310]  Y. Shoenfeld,et al.  Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. , 2007, Rheumatology.

[311]  B. S. Andrews,et al.  The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. , 1988, Arthritis and rheumatism.

[312]  P. Gosse,et al.  Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study , 2007, Journal of hypertension.

[313]  D. Pisetsky,et al.  The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[314]  S. Jimenez,et al.  Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. , 1992, Arthritis and rheumatism.

[315]  O. Meyer,et al.  Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. , 1983, Clinical and experimental rheumatology.

[316]  T. Medsger,et al.  Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25‐YEAR EXPERIENCE WITH 68 CASES , 1983, Medicine.

[317]  M. Tikly,et al.  Lipid peroxidation and trace elements in systemic sclerosis , 2006, Clinical Rheumatology.

[318]  H. Maricq,et al.  A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. , 1982, The American journal of medicine.

[319]  S. Gay,et al.  Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement , 2004, Annals of the rheumatic diseases.

[320]  J. Belch,et al.  Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. , 1999, The Journal of rheumatology.

[321]  E. Tan,et al.  Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. , 1983, Clinical and experimental rheumatology.

[322]  R. Abbate,et al.  High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. , 2002, The American journal of medicine.

[323]  A. Herrick,et al.  Vascular function in systemic sclerosis , 2000, Current opinion in rheumatology.

[324]  J. Lekakis,et al.  Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. , 1998, American heart journal.

[325]  O. Hornstein,et al.  Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? , 1993, The Journal of investigative dermatology.

[326]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[327]  J. Tervaert,et al.  Anti-endothelial cell antibodies in systemic sclerosis , 2010, Annals of the rheumatic diseases.

[328]  Y. Ikeda,et al.  Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.

[329]  E. Skopińska-Różewska,et al.  Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. , 1986, The Journal of investigative dermatology.

[330]  O. Ishikawa,et al.  Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis , 2006, The British journal of dermatology.

[331]  J. Fiessinger,et al.  Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. , 1982, Acta dermato-venereologica.

[332]  H. Worthington,et al.  Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. , 1996, The Journal of rheumatology.

[333]  D. Scott,et al.  Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins. , 1985, Annals of the rheumatic diseases.

[334]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[335]  Abraham,et al.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers , 1998, Clinical and experimental immunology.